Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study

Blood Adv. 2024 Mar 26;8(6):1415-1419. doi: 10.1182/bloodadvances.2023010959.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Clinical Trial, Phase II

MeSH terms

  • Anemia, Aplastic* / drug therapy
  • Follow-Up Studies
  • Humans
  • Receptors, Fc*
  • Recombinant Fusion Proteins / adverse effects
  • Thrombopoietin / adverse effects

Substances

  • romiplostim
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • Receptors, Fc